ライフサイエンスコーパス: ischemic

1 vascular disease), 128294 from stroke (16125 ischemic, 32591 hemorrhagic, and 79578 other), and 67914

2 ial proportion of patients and is limited by ischemic adverse events.

3 lar to wild-type aged hearts (i.e., impaired ischemic AMPK activation and higher sensitivity to ische

4 Of interest, ischemic AMPK activation was blunted in aged hearts comp

5 ased Sesn2 levels in aging lead to a blunted ischemic AMPK activation, alterations in substrate metab

6 The risk of recurrent ischemic and bleeding events after primary percutaneous

7 implicated in the regulation of development, ischemic and dilated cardiomyopathy, and myocardial infa

8 city are nonmodifiable risk factors for both ischemic and hemorrhagic stroke, while hypertension, smo

9 icans experienced higher mortality rates for ischemic and hypertensive heart disease compared with ot

10 relative risk of HF overall and by subtype (ischemic and nonischemic HF) in patients with RA and to

11 o the tissue damage and can be reversible in ischemic and traumatic injuries.

12 tion of O-GlcNAcylation was also seen in the ischemic areas of postmortem human brains.

13 atients with an ischemic stroke or transient ischemic attack and insulin resistance, those at higher

14 ED visits resulted in a stroke or transient ischemic attack diagnosis.

15 or operative mortality (<30 days), transient ischemic attack in 1 patient, reoperation for bleeding i

16 PET/CT in 26 patients after recent transient ischemic attack or minor ischemic stroke: 18 patients wi

17 older with a history of stroke or transient ischemic attack to achieve a target systolic blood press

18 y of stroke, systemic embolism, or transient ischemic attack was 39.4%/y versus 30.3%/y without (P=0.

19 acterize death and CVEs (stroke or transient ischemic attack) after HRDM procedures over a 17-year pe

20 myocardial infarction, stroke, and transient ischemic attack) and venous thromboembolism (VTE).

21 abetes mellitus, 30%; prior stroke/transient ischemic attack, 6.5%; arterial disease, 15.9%; all CHAD

22 n America, older age, prior stroke/transient ischemic attack, and aspirin use at baseline.

23 After an ischemic stroke or transient ischemic attack, patients at higher risk for stroke or M

24 ction [MI], heart failure, stroke, transient ischemic attack, peripheral arterial complication, and c

25 romboembolic events, MI, stroke or transient ischemic attack, vascular deaths, and major vascular eve

26 resistance and a recent stroke or transient ischemic attack.

27 IQR]: 0.22 to 1.15; p = 0.008) and transient ischemic attack/stroke (median difference: 0.13; IQR: 0.

28 ere was a similar number of stroke/transient ischemic attack/systemic embolic events (6 versus 10, iE

29 ; P=0.03) and with more strokes or transient ischemic attacks (55 [0.9%] versus 34 [0.5%]; odds ratio

30 he rapid decline in neuronal function during ischemic attacks and acute severe hypoglycemia.

31 recrudescence from mimics, such as transient ischemic attacks, migraine, Todd paralysis, and Uhthoff

32 subjects), and in 72 patients with transient ischemic attacks.

33 cient to induce astrocytic activation in the ischemic brain and that astrocytes activated by neuronal

34 that uPA and uPAR expression increase in the ischemic brain during the recovery phase from an acute i

35 rebral artery occlusion, or neonatal hypoxic-ischemic brain injury, Mn preferentially accumulated in

36 at platelets help maintain hemostasis in the ischemic brain, their exact contribution remains ill def

37 tional recovery and endogenous repair in the ischemic brain.

38 talk that promotes synaptic recovery in the ischemic brain.

39 urons that promotes synaptic recovery in the ischemic brain.SIGNIFICANCE STATEMENT To date, there is

40 se and may promote progenitor cell homing to ischemic calf muscle.

41 oregulated genes could be confirmed in human ischemic cardiac tissue samples.

42 cardioverter defibrillator (ICD) therapy in ischemic cardiomyopathy (ICM) and nonischemic cardiomyop

43 METHODS AND Thirty patients with ischemic cardiomyopathy received in a blinded manner eit

44 Gottingen swine with experimental ischemic cardiomyopathy were randomized to receive trans

45 Among all patients (164 ischemic cardiomyopathy, 150 nonischemic dilated cardiom

46 ithout DM, those with DM had higher rates of ischemic cardiomyopathy, LVAD implantation as destinatio

47 modeling in mice with large infarcts, and in ischemic cardiomyopathy, they improve LV function, effec

48 s scar size and improves cardiac function in ischemic cardiomyopathy.

49 Cardiovascular surgery with ischemic cardioplegic arrest is only a surrogate of acut

50 to RIPC and to protect the myocardium during ischemic cardioplegic arrest.

51 score) in a cohort of 351 adults at risk for ischemic cardiovascular disease.

52 acilitated the discovery of a feature of the ischemic cascade: selective loss of smooth muscle cells

53 Here we show that ischemic cell death and uptake of cell debris by macroph

54 nsitivity of spectral analysis to oncosis or ischemic cell death had not previously been studied.

55 ebral embolic protection devices in reducing ischemic central nervous system (CNS) injury during SAVR

56 nd 17 acutely symptomatic patients ([urgent] ischemic cerebrovascular event within the previous 5 day

57 Concerns for ischemic cholangiopathy (IC), a disease of diffuse intra

58 nd mortality; especially if complicated with ischemic colitis, stercoral ulcer formation and subseque

59 tests have thus no added benefit to prevent ischemic complications of the hand.

60 ing cells in the LV myocardium in normal and ischemic conditions 7 days after complete ligature of th

61 re-activate CPC regenerative potential under ischemic conditions.

62 ied as "target mismatch" if they had a small ischemic core and a large penumbra on their baseline CT

63 n, a stricter rCBF threshold to estimate the ischemic core should be considered.

64 baseline computed tomography perfusion (CTP) ischemic core threshold to predict infarction as thrombo

65 Despite similar baseline CTP ischemic core volumes using the previously validated mea

66 the outcomes of patients with large baseline ischemic cores on CTP undergoing ET with the outcomes of

67 ng high-density encapsulation to normoxic or ischemic culture for 12 hours, after which viability and

68 e system to protect liver grafts from lethal ischemic damage before transplantation in a clinically r

69 ss the effect of inhaled xenon on myocardial ischemic damage in the same study population.

70 e extent of ischemia (hazard ratio for small ischemic defects: 2.2, 95% confidence interval [CI], 0.9

71 ectively; hazard ratio for moderate or large ischemic defects: 4.0, 95% CI, 1.5-10.5 and 12.1, 95% CI

72 ND Ninety-nine patients with ischemic or non-ischemic dilated cardiomyopathy undergoing prophylactic

73 and clinical evaluation for the treatment of ischemic diseases.

74 onates (>/=36 weeks' gestation) with hypoxic-ischemic encephalopathy at 18 US centers in the Eunice K

75 died had a cause of death other than hypoxic-ischemic encephalopathy.

76 lity at 18 months among infants with hypoxic-ischemic encephalopathy.

77 Secondary ischemic end points were also evaluated.

78 stinal thrombotic microangiopathy (iTMA) and ischemic enteritis in approximately 50% of infected huma

79 The annualized mortality rate after an ischemic event was 27.2 (95% CI, 20.3-35.7) per 100 pers

80 andomization, 478 individuals (4.1%) had 502 ischemic events (306 with myocardial infarction, 113 wit

81 ly associated with increased risks of severe ischemic events (cause-specific hazard, 2.12 [1.14-3.96]

82 The effect of cangrelor on ischemic events and bleeding was analyzed in the subgrou

83 ials reduced the 48-hour and 30-day rates of ischemic events during percutaneous coronary interventio

84 ectomy is associated with higher rates of CV ischemic events in older patients and those with a histo

85 T scores undergoing PCI but reduced risk for ischemic events in patients with high scores receiving p

86 f antiplatelet therapy for the prevention of ischemic events in stable patients with symptomatic athe

87 MACE but a higher adjusted risk of recurrent ischemic events primarily because of nonstent-related MI

88 been associated with a high risk of adverse ischemic events, but there is a paucity of contemporary

89 vascular disease and subsequent injury after ischemic events, fundamental knowledge in these areas la

90 syndrome are at heightened risk of recurrent ischemic events, including stroke.

91 -lesion anatomy is associated with increased ischemic events, particularly within the first year afte

92 a considerably higher risk of 2-year adverse ischemic events, with HPR conferring similar risk in SVG

93 in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction) (

94 and lessen both the frequency and impact of ischemic events.

95 End-ischemic ex situ NMP results in activation of fibrinolys

96 Islet viability after acute ischemic exposure was reduced compared to normoxic cultu

97 hemokines, and significantly alleviated post-ischemic expression of inflammatory mediators.

98 The severity of the various ischemic fundus and retinal lesions and of the optic dis

99 at the 90th and 10th percentile was 2.0 for ischemic heart disease (119.1 vs 235.7 deaths per 100000

100 zations, whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent cha

101 lung cancer (HR = 1.08, 95% CI: 1.02, 1.14), ischemic heart disease (HR = 1.09, 95% CI: 1.02, 1.16),

102 The pathogenic role of ischemic heart disease (IHD) in heart failure (HF) with

103 rheumatoid arthritis (RA) is independent of ischemic heart disease (IHD).

104 Ischemic heart disease (odds ratio [OR], 7.21; P < 0.001

105 tment in improving survival in patients with ischemic heart disease and reduced ejection fraction.

106 rpose We aimed to predict individual risk of ischemic heart disease and stroke in 5-year survivors of

107 Results Ischemic heart disease and stroke occurred in 265 and 29

108 through age 50 years for the development of ischemic heart disease and stroke.

109 ques in coronary arteries from patients with ischemic heart disease implying a role in human arterial

110 HF was higher in patients with a history of ischemic heart disease or atrial fibrillation.

111 Ischemic heart disease resulting from myocardial infarct

112 in patients with congestive heart failure or ischemic heart disease than in those without (P = 0.021

113 y, peripheral neuropathy, diabetic foot, and ischemic heart disease were 21.9%, 17.6%, 28.0%, 6.2%, a

114 n patients with hypertrophic cardiomyopathy, ischemic heart disease, diabetes mellitus, and more.

115 Twenty sepsis patients, 11 ischemic heart disease, nine dilated cardiomyopathy, and

116 s between ingestion of inorganic arsenic and ischemic heart disease, nonmalignant respiratory disease

117 altered abundance in septic cardiomyopathy, ischemic heart disease, or dilated cardiomyopathy, in co

118 s with acute myocardial infarction or stable ischemic heart disease.

119 of cardiac stem/progenitor cell therapy for ischemic heart disease.

120 tion of PM2.5 with circulatory mortality and ischemic heart disease.

121 also be confirmed in patients suffering from ischemic heart disease.

122 y age, sex, time of symptom onset, and known ischemic heart disease.

123 larizing damaged myocardium in patients with ischemic heart disease.

124 larization is an effective means of treating ischemic heart disease; however, current therapeutic rev

125 tained inflammation is a hallmark of chronic ischemic heart failure (HF); however, the pathophysiolog

126 with hs-TnT levels in patients with chronic ischemic heart failure (P=0.0008, n=10, triple measureme

127 transplantation of isolated mitochondria to ischemic heart tissue leads to decreases in cell death,

128 pillary density further decreased in chronic ischemic hearts, as did EF (both p < 0.05).

129 A first-ever HF diagnosis (classified as ischemic HF or nonischemic HF based on the presence of I

130 to reverse cardiac dysfunction in a model of ischemic HF.

131 y after RA onset, in contrast to the risk of ischemic HF.

132 tive therapeutic target for treating hypoxic-ischemic human diseases and organ transplantation.

133 cental pathologies of inflammatory, hypoxic, ischemic/hypertensive, infectious and thrombotic etiolog

134 have clinical application in protection from ischemic-induced renal injury.

135 all the PCAs resulted in the development of ischemic infarction of the choroid, retinal pigment epit

136 rain during the recovery phase from an acute ischemic injury and that uPA binding to uPAR promotes ne

137 1A, could lead to neuroprotection following ischemic injury in vivo The minimal syntaxin 1A-binding

138 Cardiac ischemic injury induces a pathological remodeling respon

139 Ischemic injury represents the most frequent cause of de

140 Severe global ischemic injury was induced by bilateral common carotid

141 al hemorrhage, hemorrhagic transformation of ischemic injury, and presumed perinatal hemorrhagic stro

142 tion to the intercalated discs against acute ischemic injury.

143 ioprotective capabilities against myocardial ischemic injury.

144 ox9 blunted the cardiac fibrotic response on ischemic injury.

145 ng to cyclin D/Cdk4/pRb activation following ischemic insult are presently not clear.

146 lurane or sevoflurane administered after the ischemic insult reduced brain infarct percentage and neu

147 metabolism, and an increased sensitivity to ischemic insults.

148 Moreover, ischemic kidneys had higher levels of Rac1-GTP, required

149 Intravital imaging of post-ischemic kidneys revealed reduced vascular leak with alp

150 acute lesions, P = .088; chronic subcortical ischemic lesions, P = .085).

151 after ligation, neutrophil infiltration into ischemic limbs of AMPKalpha2(DeltaMC) mice was lower tha

152 notypic changes are functionally relevant as ischemic macrophages triggered tube-like morphogenesis i

153 d 2) to analyze how LA remodeling influences ischemic MR development.

154 Development of ischemic MR was more pronounced in the LAI group than in

155 ffects of left ventricular (LV) dysfunction, ischemic MR, and left atrial infarction (LAI); and 2) to

156 ischemic skeletal muscle cells and enhanced ischemic muscle autophagic flux.

157 BAG3(Ile81), but not BAG3(Met81), improved ischemic muscle myopathy and muscle precursor cell diffe

158 production to induce M2-like polarization in ischemic muscle to enhance angiogenesis, arteriogenesis,

159 Flow cytometric analysis of ischemic muscles at day 2 revealed increased myeloid lin

160 lated on resident vascular cells from murine ischemic muscles, thus providing a permissive milieu to

161 olds may significantly improve recovery from ischemic myocardial injury.

162 orphonuclear neutrophils, accumulates within ischemic myocardium and has been linked to adverse left

163 In humans, T2 relaxation time in the ischemic myocardium declines significantly from early af

164 hermore, red wine significantly reduced post-ischemic neutrophil infiltration.

165 of these were misdiagnosed as glaucoma (two ischemic optic neuropathies and two congenital optic dis

166 dema (CME; n = 3), and nonarteritic anterior ischemic optic neuropathy (n = 1) in the repositioning g

167 hemic syndrome (OIS), non-arteritic anterior ischemic optic neuropathy (NA-AION) and amaurosis fugax

168 have a greater risk of nonarteritic anterior ischemic optic neuropathy (NAION) than nondiabetic patie

169 thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regim

170 role of SMR in the outcomes of patients with ischemic or idiopathic cardiomyopathies.

171 METHODS AND Ninety-nine patients with ischemic or non-ischemic dilated cardiomyopathy undergoi

172 Early revascularization of ischemic organs is key to improving outcomes, yet conseq

173 he common denominator of ischemia within all ischemic organs, played no apparent role.

174 not associated with a lower risk of primary ischemic outcome at 180 days (odds ratio, 0.96; 95% conf

175 patients (median age 64 years, 73% male, 30% ischemic pathogenesis) were enrolled.

176 cial actions of ischemic preconditioning and ischemic postconditioning by a mechanism stemming primar

177 urther blindly applied to plasma from remote ischemic pre-conditioning (RIPC) rats.

178 Remote ischemic preconditioning (RIPC) by repeated brief cycles

179 erase-5 inhibitors and beneficial actions of ischemic preconditioning and ischemic postconditioning b

180 erved for comparisons involving xanthine and ischemic preconditioning, although the impact of NAC and

181 n of the cGMP-degrading phosphodiesterase-5, ischemic preconditioning, and postconditioning regimens.

182 or single-vessel ischemia, and severe=large ischemic region abnormality).

183 t is also implicated in pathogenesis of post-ischemic remodeling in several organs in human.

184 Post-ischemic reperfusion injury (PIRI) triggers an intense i

185 sed hepatocellular injury when exposed to an ischemic-reperfusion insult.

186 etal protein paxillin, growth factor-induced ischemic retinopathy in the murine oxygen-induced retino

187 cangrelor alone was associated with similar ischemic risk and lower risk-adjusted bleeding risk comp

188 It remains unclear whether ischemic risk and the benefits of prolonged P2Y12 inhibi

189 ascular events; however, they also had lower ischemic risk.

190 Females show a varying degree of ischemic sensitivity throughout their lifespan, which is

191 g to the small heat shock protein (HspB8) in ischemic skeletal muscle cells and enhanced ischemic mus

192 ropriately activated in mature neurons under ischemic stress conditions.

193 at Cdc25A is activated in neurons undergoing ischemic stress mediated by hypoxia in vitro and global

194 onstrate a cardiac phenotype and response to ischemic stress that is similar to wild-type aged hearts

195 either mutation impacted cardiac response to ischemic stress, isolated hearts were subjected to ische

196 in, driven by a significant 21% reduction in ischemic stroke (3.4% versus 4.1%; HR, 0.79; 95% CI, 0.6

197 60; 95% CI, 0.38-0.95; P=0.030) and 7.6% for ischemic stroke (8.7% versus 16.3%; number needed to tre

198 ent use of intravenous thrombolysis in acute ischemic stroke (AIS).

199 iated with a significant increase in risk of ischemic stroke (hazard ratio, 1.18; 95% confidence inte

200 y (HR, 0.83; 95% CI, 0.70-0.98; P=0.029) and ischemic stroke (HR, 0.76; 95% CI, 0.63-0.91; P=0.003).

201 morrhage (HR, 2.4; 95% CI, 1.7-3.5) than for ischemic stroke (HR, 1.3; 95% CI, 1.2-1.5).

202 d biomarkers with clinical utility for acute ischemic stroke (IS).

203 he complex relationship between migraine and ischemic stroke (IS).

204 Intracerebral hemorrhage and ischemic stroke admissions were identified from the Nati

205 The incidence of ischemic stroke among young adults is rising and is pote

206 ular events including myocardial infarction, ischemic stroke and cardiovascular death, quality-adjust

207 ovascular hemorrhage in mouse models of both ischemic stroke and glioblastoma, accompanied by reduced

208 Here we show that in patients with ischemic stroke and in mice subjected to middle cerebral

209 rvational study of 94474 patients with acute ischemic stroke and known history of AF admitted from Oc

210 To avoid the occurrence of early ischemic stroke associated with childhood overweight and

211 d ischemic stroke in a separate study of 509 ischemic stroke cases (202 cardioembolic [40%]) and 3028

212 ble clinical outcomes in patients with acute ischemic stroke caused by intracranial proximal occlusio

213 e or those who had previously experienced an ischemic stroke displayed a higher risk of stroke if war

214 observed in 2.5% of the patients with acute ischemic stroke due to large vessel occlusion and were m

215 Although ischemic stroke has been found to be associated with man

216 s in this study are as follows: first, acute ischemic stroke hospitalization rates increased signific

217 ociations between AF genetic risk scores and ischemic stroke in a separate study of 509 ischemic stro

218 amen ovale reduces the risk of recurrence of ischemic stroke in patients who have had a cryptogenic i

219 n of ASIC1a reduces neuronal death following ischemic stroke in rodents.

220 al trial of endovascular treatment for acute ischemic stroke in the Netherlands.

221 3 years was positively associated with early ischemic stroke in women (HR, 1.10; 95% CI, 1.01-1.20) a

222 Consecutive patients with acute ischemic stroke initially admitted to a non-thrombectomy

223 evolution for thrombectomy in patients with ischemic stroke initially transferred to non-TCSCs.

224 PV1-mediated hypothermia by DHC on long-term ischemic stroke injury and functional outcome.

225 iological pathways, the genetic mechanism of ischemic stroke is still unclear.

226 troke in patients who have had a cryptogenic ischemic stroke is unknown.

227 therosclerotic occlusive disease is a common ischemic stroke mechanism.

228 To determine whether, among patients with an ischemic stroke or transient ischemic attack and insulin

229 After an ischemic stroke or transient ischemic attack, patients a

230 ung adenocarcinoma transcript 1 (Malat1), in ischemic stroke outcome.

231 A total of 535 332 ischemic stroke patients from 1494 GWTG-Stroke hospitals

232 One third of acute ischemic stroke patients were functionally dependent or

233 In total, 44 acute ischemic stroke patients were randomly divided to the XX

234 A total of 16 901 ischemic stroke patients were treated with intravenous t

235 ODUCTION: We aimed to identify whether acute ischemic stroke patients with known complete reperfusion

236 In ischemic stroke patients, being overweight or obese was

237 age patient with AF, the threshold of annual ischemic stroke rate where the benefit of anticoagulatio

238 In women, although ischemic stroke risk was similar in the 3 anticoagulant

239 women was partially offset by an increase in ischemic stroke risk.

240 of neutrophils and more specifically NETs in ischemic stroke thrombi.

241 n significantly reduced all-cause stroke and ischemic stroke through 77 days of follow-up

242 dbrain to label specific neuronal types, and ischemic stroke was induced in the dorsolateral striatum

243 a cryptogenic stroke, the risk of subsequent ischemic stroke was lower among those assigned to PFO cl

244 In men, the pooled relative risks of ischemic stroke were 1.19 (95% CI, 1.05-1.34) after andr

245 capable hospitals, 7.5% of all patients with ischemic stroke were treated in the third quarter of 201

246 ficacy of intravenous rt-PA in patients with ischemic stroke who are taking NOACs.

247 use of thrombolytic therapy in patients with ischemic stroke who received anticoagulation with NOACs

248 xamine the prevalence of patients with acute ischemic stroke with known history of AF who were not re

249 tion, 113 with stent thrombosis, and 83 with ischemic stroke), and 232 individuals (2.0%) had 235 ble

250 significant association between PPI use and ischemic stroke, after accounting for indications for PP

251 ) with myocardial infarction, 11 (0.9%) with ischemic stroke, and 1 (0.1%) with deep venous thrombosi

252 included a composite of mortality, clinical ischemic stroke, and acute kidney injury within 30 days

253 ng fatal and nonfatal myocardial infarction, ischemic stroke, and cardiovascular death.

254 , hospitalization for myocardial infarction, ischemic stroke, and heart failure.

255 ing numerous pathologies including migraine, ischemic stroke, aneurysmal subarachnoid hemorrhage, int

256 red a promising neuroprotective treatment of ischemic stroke, but the treatment's various complicatio

257 Ischemic stroke, intracranial hemorrhage, extracranial b

258 stics increasing stroke risk include HDP for ischemic stroke, late menopause and gestational hyperten

259 plicated in several neuronal disorders, like ischemic stroke, neuronal inflammation, and pathological

260 d incident ASCVD (ie, myocardial infarction, ischemic stroke, or fatal coronary heart disease).

261 t model of upper extremity impairments after ischemic stroke, we examined effects of motor rehabilita

262 We found that ischemic stroke-induced DLS infarction produced signific

263 diovascular death, myocardial infarction, or ischemic stroke.

264 z score was positively associated with early ischemic stroke.

265 utely symptomatic carotid disease and recent ischemic stroke.

266 romotes neurological recovery after an acute ischemic stroke.

267 g cancer, in cerebrovascular pathogenesis of ischemic stroke.

268 lly those who have previously experienced an ischemic stroke.

269 neuroprotection in an animal model of acute ischemic stroke.

270 nded strategies to reduce DTN times in acute ischemic stroke.

271 l damage and improve the clinical outcome of ischemic stroke.

272 s highly neuroprotective in a focal model of ischemic stroke.

273 nd functional outcome in patients with acute ischemic stroke.

274 id cycle intermediates in mouse brain during ischemic stroke.

275 fy potential genetic factors contributing to ischemic stroke.

276 een patients had either device thrombosis or ischemic stroke.

277 ithheld in these complex patients with acute ischemic stroke.

278 sm, chronic kidney disease, and large-artery ischemic stroke.

279 For the principal effectiveness end point of ischemic stroke/systemic embolism, no significant differ

280 er recent transient ischemic attack or minor ischemic stroke: 18 patients with culprit carotid stenos

281 vator) is effective in improving outcomes in ischemic stroke; however, there are few data on the use

282 Primary outcomes of inpatient admissions for ischemic strokes and major bleeding were compared across

283 ism accounts for an increasing proportion of ischemic strokes and might multiply several-fold during

284 ted with plaque necrosis and the presence of ischemic symptoms.

285 anch (BRAO) retinal artery occlusion, ocular ischemic syndrome (OIS), non-arteritic anterior ischemic

286 of graft loss per hour increase in the total ischemic time (adjusted hazard ratio, 1.09; 95% confiden

287 were MVO (hazard ratio, 3.418; P=0.046) and ischemic time (hazard ratio, 1.016; P<0.001).

288 on graft outcomes, such that the duration of ischemic time has the greatest impact on graft survival

289 r age, the pathway of donor death, and total ischemic time on graft outcomes, such that the duration

290 ion of some of these lncRNAs correlates with ischemic time.

291 The cold and warm ischemic times improved significantly during the second

292 y of poor ex vivo perfusion, had longer cold ischemic times, and were transplanted into older recipie

293 relevant endpoints across a spectrum of warm ischemic times, before and during ex vivo heart perfusio

294 Neutrophil survival in ischemic tissue is required to attract monocytes that co

295 estigated the mechanisms of CD34Exo-mediated ischemic tissue repair and therapeutic angiogenesis by s

296 ated molecular pattern (DAMP), released from ischemic tissues and dying cells which, when crystalized

297 particularly hand and forearm, have limited ischemic tolerance after procurement.

298 DCD grafts in particular are associated with ischemic-type biliary lesions (ITBL) with subsequent imp

299 nd the rate of neovascularization relapse in ischemic vasculitis.

300 Nonacute ischemic white matter changes on T2-weighted imaging, fo